Disease activity return after natalizumab cessation in multiple sclerosis

Rasenack, M. and Derfuss, T.. (2016) Disease activity return after natalizumab cessation in multiple sclerosis. Expert Review of Neurotherapeutics, 16 (5). pp. 587-594.

Full text not available from this repository.

Official URL: https://edoc.unibas.ch/61664/

Downloads: Statistics Overview


Natalizumab (NAT) was the first monoclonal antibody to be approved for the treatment of relapsing-remitting multiple sclerosis. Its considerable and sustained efficacy has been demonstrated in two phase III studies. However, there are several reasons why its use is limited in clinical practice. The main argument for stopping use of the drug is the risk of the rare but serious progressive multifocal leukencephalopathy. Other reasons are neutralizing antibodies and pregnancy. There is compelling evidence from some clinical trials and many case series that disease activity returns upon suspension or cessation of NAT. Several therapeutic strategies that have been tested to prevent or reduce the recurrence of disease activity will be reviewed in this article. Considering these data, it is evident that the decision to stop NAT treatment has different implications and consequences. A subsequent therapy after cessation of NAT is needed to reduce the risk of disease recurrence.
Faculties and Departments:03 Faculty of Medicine > Departement Biomedizin > Department of Biomedicine, University Hospital Basel > Clinical Neuroimmunology (Derfuss/Lindberg)
UniBasel Contributors:Derfuss, Tobias Johannes
Item Type:Article, refereed
Article Subtype:Further Journal Contribution
Note:Publication type according to Uni Basel Research Database: Journal item
Identification Number:
Last Modified:30 Apr 2019 15:38
Deposited On:30 Apr 2019 15:38

Repository Staff Only: item control page